Would you like to participate ask a question join the surfers in our next episode?

S2-E54.2 – Inside the Patient-Focused Drug Development Meeting: The Advocates’ Perspectives

Global Liver Institute Founder, President and CEO Donna Cryer and her fellow patient and patient advocate Terri Milton join Stephen Harrison, Louise Campbell and Roger Green to discuss the ground-breaking NASH Patient-Focused Drug Development meeting held on November 4, 2021 and the advocates' perspectives that individuals brought to the meeting.

In this conversation, Global Liver Institute Founder, President, and CEO Donna Cryer describes the history of the basic Patient-Focussed Drug Development concept and this particular Fatty Liver event. Patient and patient advocate Terri Milton discusses the message she hoped regulators would take away from this session and why she believes the group may have succeeded. Finally, the group discusses why regulators and advocates vary so greatly in terms of how they view the efficacy: safety tradeoff for first-in-class drugs.

Request Transcript of This Episode
Request Transcript
First
Last

NASH & Diabetes Podcast and NASH Tsunami Podcast